Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to $57.5 million.

  • Tg Therapeutics' Short-term Investments fell 6040.39% to $57.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.5 million, marking a year-over-year decrease of 6040.39%. This contributed to the annual value of $131.1 million for FY2024, which is 524.26% up from last year.
  • Per Tg Therapeutics' latest filing, its Short-term Investments stood at $57.5 million for Q3 2025, which was down 6040.39% from $122.7 million recorded in Q2 2025.
  • In the past 5 years, Tg Therapeutics' Short-term Investments registered a high of $145.2 million during Q3 2024, and its lowest value of $15.9 million during Q4 2021.
  • Its 5-year average for Short-term Investments is $82.1 million, with a median of $66.1 million in 2022.
  • Its Short-term Investments has fluctuated over the past 5 years, first plummeted by 6946.16% in 2021, then soared by 27398.59% in 2022.
  • Over the past 5 years, Tg Therapeutics' Short-term Investments (Quarter) stood at $15.9 million in 2021, then skyrocketed by 273.99% to $59.4 million in 2022, then surged by 109.81% to $124.6 million in 2023, then rose by 5.24% to $131.1 million in 2024, then plummeted by 56.14% to $57.5 million in 2025.
  • Its last three reported values are $57.5 million in Q3 2025, $122.7 million for Q2 2025, and $144.1 million during Q1 2025.